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ABSTRACT 14 
The protozoan parasite Leishmania donovani is the causative agent of visceral 15 
leishmaniasis, a disease potentially fatal if not treated. Current available treatments have 16 
major limitations and new and safer drugs are urgently needed. In recent years, 17 
advances in high throughput screening technologies have enabled the screening of 18 
millions of compounds to identify new antileishmanial agents. However, most of the 19 
compounds identified in vitro did not translate their activity when tested in in vivo 20 
models, highlighting the need to develop more predictive in vitro assays. In the present 21 
work, we describe the development of a robust replicative, high content, in vitro 22 
intracellular L. donovani assay. Horse serum was included in the assay media to replace 23 
standard foetal bovine serum to completely eliminate the extracellular parasites derived 24 
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from the infection process. A novel phenotypic in vitro infection model has been 25 
developed complemented with the identification of the proliferation of intracellular 26 
amastigotes  measured by EdU incorporation.   27 
In vitro and in vivo results for miltefosine, amphotericin B and the selected compound 1 28 
have been included to validate the assay.  29 
 30 
Introduction 31 
The leishmaniases are a complex of diseases, with visceral and cutaneous 32 
manifestations caused by protozoan parasites of the genus Leishmania.  Visceral 33 
leishmaniasis (VL) has been the main focus for drug R&D over the past two decades, 34 
due to the large disease burden in East Africa and South Asia (1) and potential patient 35 
death if not treated. For VL, there has been progress in treatment over the past decade 36 
with clinical evidence for efficacy of, and registration for use of oral miltefosine, 37 
paromomycin and the liposomal formulation of amphotericin B (AmBisome™) in 38 
South Asia (2), as well as combinations of these standard drugs (3). The need for new 39 
drugs to treat VL remains, as (i) miltefosine is the only approved oral treatment but 40 
requires 28 days of treatment and potential teratogenicity limits its use (4), (ii) 41 
paromomycin  requires 21 days of treatment and intramuscular administration 42 
(http://www.dndi.org/diseases-projects/diseases/vl/current-treatment/current-treatment-43 
vl.html) and (iii) liposomal amphotericin B formulations, which have successful cure 44 
rates with a single dose (5), require intravenous infusion, have a high cost if not donated 45 
and the requirement for cold storage, limiting use in countries where the disease is 46 
endemic (6). As part of the drive to find new treatments there has been a re-focus on the 47 
assays and models used to identify and develop new molecules as antileishmanial drugs. 48 
For in vitro screens and assays, this has ranged from the need to develop methods, that:  49 
(i) Are adaptable to and enable high throughput screens against the replicative 50 
intracellular – macrophage amastigote stage of Leishmania donovani, one of 51 
the causative species of VL (7). 52 
(ii) Include high throughput technologies that enable the collection of more 53 
information compared to the traditionally used assays based on manual 54 
counting and reporter genes (8, 9). For example, High Content Screening 55 
(HCS) systems that permit the screening of large sets of compounds using 56 
imaging techniques that also capture  information about compounds’ toxicity 57 
against host cells and mode of action (10, 11) have been applied to 58 
antileishmanial drug discovery (12-17).  59 
In this paper, we describe methods to overcome some of critical issues related to 60 
reproducibility and biological relevance and to  the replication of the intracellular 61 
parasite. 62 
The role of replication rate of intracellular amastigotes on interpretation of data from 63 
assays if often ignored. In vivo we know that in the L. donovani mouse  model the 64 
parasite load in the liver increased 20-fold over the initial eight days (18) and in the L. 65 
donovani hamster model the parasite burden increased more than 6 logs in the spleen 66 
and 4 logs in the liver over the 56 days of the study (19). Recent experiments reported a 67 
doubling time of two days in an ex vivo splenic explant model system established 21 68 
days post infection developed by the same group (20). We determined the replication 69 
rate of intracellular amastigotes in our assay using an adaptation of a classical 70 
nucleotide analogue incorporation assay (21) to enable visual identification of cells 71 
actively replicating within macrophage vacuoles. 72 
 73 
 MATERIALS AND METHODS 74 
 75 
Cell Lines 76 
THP-1 cells (human monocytic leukemia) were made available by GSK-Biological 77 
Reagents and Assay Development Department (BRAD, Stevenage, UK) and were 78 
maintained in RPMI media (Life-Technologies) supplemented with 1.25 mM Pyruvate 79 
(Life-Technologies), 2.5 mM Glutamine (Life-Technologies), 25 mM  HEPES (Life-80 
Technologies) and 10% heat inactivated FBS (Gibco).  81 
Leishmania donovani (MHOM/SD/62/1SCL2D, LdBOB) expressing green fluorescence 82 
protein (GFP) (14) was kindly provided by Manu de Rycker, University of Dundee, 83 
UK. Axenic amastigotes were maintained at 37ºC, 5% CO2 in media containing 15 mM 84 
KCl solution (Invitrogen), 10 mM KH2PO4 (Merck), 136 mM KH2PO4 (Merck), 0.5 85 
mM  MgSO4 (Sigma-Aldrich), 24 mM NaHCO3 (Invitrogen), 25 mM Glucose (Sigma-86 
Aldrich), 1mM L-Glutamine (Invitrogen), 1xRPMI Vitamin Solution (Sigma-Aldrich), 87 
10 µM Folic Acid (Sigma-Aldrich), 100 µM Adenosine (Sigma-Aldrich), 5mg/L Hemin 88 
(Sigma-Aldrich), 1xRPMI Amino Acid solution (Sigma-Aldrich), 25 mM MES, 89 
0.0004% Phenol Red and 20% Heat Inactivated FBS (Gibco) in Milli-Q water. The 90 
selection antibody Nourseothricin (Jena Bioscience) was regularly added to the cultures 91 
of amastigotes. Promastigotes were maintained at 30ºC in M199 Media (Sigma Aldrich) 92 
supplemented with 25mM HEPES (Invitrogen), 12mM NaHCO3 (Invitrogen), 1mM L-93 
Glutamine (Invitrogen), 1xRPMI Vitamin Solution (Sigma-Aldrich), 10µM Folic Acid 94 
(Sigma-Aldrich), 100µM Adenosine (Sigma-Aldrich), 5mg/L Hemin and 10% Heat 95 
Inactivated FBS (Gibco) (14).  96 
 97 
In vitro intra-macrophage L. donovani assay 98 
The intra-macrophage assay was adapted from de Rycker et al. (14) and Peña et al. (16). 99 
THP-1 cells were grown in CELLMASTER roller bottles (Greiner cat. # 680048) at an 100 
initial seeding concentration of 2x10
5
 cells/mL for 72 h. Cells were visually inspected 101 
with an optical microscope and counted with a CASY Counter (model TT, Roche). 102 
Cells were differentiated in a 225 cm
3
 T-FLASK (80 ml) in the presence of 30 nM of 103 
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) at a final concentration of 6x10
5
 104 
cells/mL. Following 24h incubation at 37C, 5% CO2, differentiation was visually 105 
confirmed checking the confluence of the differentiated adherent monolayer and PMA-106 
containing media was removed washing twice with complete growth media, taking care 107 
of not disrupting the cell layer. 108 
Each T-flask containing differentiated THP-1 cells was infected with 80 mL of a 109 
suspension of 6x10
6
 parasites/mL in THP-1 complete growth media without PMA and 110 
incubated additional 24h. The media was removed and the cell monolayer washed with 111 
PBS. The infected cells were harvested by treatment with a solution of 0.25% (w/v) 112 
trypsin/EDTA in PBS and seeded in assay plates (1.6x10
5
 cells/mL, 50 µl/well) in assay 113 
media, containing RPMI media supplemented with 2% Heat Inactivated Horse Serum 114 
(Gibco) or Foetal Bovine Serum (Gibco), 25 mM NaHCO3 (Invitrogen™) and 30 nM 115 
PMA using a Multidrop Combi dispenser (Thermo Scientific). A parallel culture of 116 
uninfected differentiated THP-1 cells was treated as described for infected cells and 117 
used as control for 100% compound response. Assay plates were incubated at 37C, 5% 118 
CO2 for the time required for the assay and then fixed with 4% formaldehyde for 30 min 119 
at room temperature adding 50 µl of 8% (v/v) formaldehyde solution (Sigma-Aldrich) 120 
in PBS to each well containing 50 µl of media. After fixation, cells were washed twice 121 
with 100 μL PBS using an EL406 multi well platewasher (BioTek), stained with 30 µl 122 
of a solution of DAPI (10μg/mL) and 0.1% (v/v) Triton X-100 in PBS for 30 min at 123 
room temperature and washed additional two times with 50 μL PBS. Finally, 50 μL of 124 
PBS were added to each well, plates were sealed and stored at 4ºC until analysis.  125 
  126 
Image analysis 127 
Automated image analysis was performed with an image analysis algorithm developed 128 
on Acapella
®
 High Content Imaging and Analysis Software (PerkinElmer). THP-1 cells 129 
count (MAC) and average number of amastigotes per macrophage (AM/MAC) were 130 
calculated for each well, using the building blocks included in the analysis program. 131 
Briefly, the nuclei and cytoplasm for each macrophage were selected using DAPI stain. 132 
Amastigotes were detected as spots using the GFP signal and were filtered using area 133 
and roundness. In EdU incorporation experiments (ibid.), the number of parasites’ 134 
nuclei that were labeled was used to determine the incorporation of the thymidine 135 
analogue in the nuclei. Images were taken with a High-Content Screening System 136 
(Opera QEHS, Perkin Elmer) with a 20x air objective, acquiring a minimum of four 137 
fields per well. Two or three sequential images were taken for each well exciting at 405 138 
nm (DAPI), 488 nm (GFP) and 635 nm (EdU).  139 
 140 
Compounds and assay plates 141 
Amphotericin B and miltefosine were purchased from Sigma Aldrich. Compound 1 was 142 
available from the GSK collection of compounds (Table 1). 143 
Pre-dispensed assay plates (Greiner µclear black, 384-well) were prepared by adding 144 
250 nL of compounds dissolved in 100% DMSO or 250 nL of DMSO to each well by 145 
using an Echo® liquid handler (Labcyte Inc.). Eleven-point one in three dilution curves 146 
were generated from a top concentration of 50 μM.  147 
Plates were stored at -20C until use and allowed to equilibrate at room temperature 148 
before addition of the cell suspension.  149 
 150 
Data analysis 151 
Data were normalized to percentage biological response by using positive (i.e. highest 152 
response represented by non-infected cells, RCtrl2), or negative (i.e. lowest response 153 
achieved in the absence of any testing compound, RCtrl1) controls by using the following 154 
equation (Equation 1): 155 
%𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 =  
|𝑅𝐶𝑡𝑟𝑙1 − 𝑅𝑥|
|𝑅𝐶𝑡𝑟𝑙1 − 𝑅𝐶𝑡𝑟𝑙2|
 ⋅  100 
where Rx is the assay response measured for each compound X. RCtrl1 and RCtrl2 were 156 
included in each assay plate and calculated as the average of the replicates. 157 
Assay performance statistics, such as signal to background ratio and Z′ (22) were 158 
calculated using templates in ActivityBase XE (IDBS, Guilford, Surrey, UK). Activities 159 
were expressed as pEC50 (pEC50 = -Log EC50 (M)). Values of pEC50 were obtained 160 
using the ActivityBase XE nonlinear regression function in the full curve analysis 161 
bundle to fit the 4-parameter logistic equation. 162 
 163 
Biosafety and animal use 164 
Experimental procedures with L. donovani were carried out following standard 165 
operating procedures in compliance with biosafety level 3 regulations (BSL3). THP-1 166 
cells were treated according to GSK policies for the manipulation of human biological 167 
samples.  168 
The protocols used for animal studies were approved by the Diseases of the Developing 169 
World (DDW-GSK) ethical committee. The animal research complied with Spanish and 170 
European Union legislation (European directive 86/609/EEC) on animal research and 171 
GlaxoSmithKline 3R policy on the care and use of animals: Replacement, Reduction 172 
and Refinement.  173 
Additional in vivo experiments were carried out at the London School of Hygiene & 174 
Tropical Medicine. These were performed under licence, issued by the UK Home Office 175 
Animal (Scientific Procedures) act 1986 and EU Directive 2010/63/EU. 176 
 177 
EdU Incorporation 178 
THP-1 cells were differentiated, infected and seeded in 384-wells plates as previously 179 
described and incubated in horse serum-containing assay media. For the optimization of 180 
EdU (Click-iT® Plus Alexa Fluor® 647 Picolyl Azide Toolkit, Lifetech) conditions (13, 181 
23), concentrations ranging from 1 to 100 µM were added to different wells at time 0 182 
and every 12 hours for 72 hours, when cells were fixed with 4% formaldehyde for 30 183 
minutes.  184 
For intracellular amastigotes replication experiments, EdU was added 24 hours after 185 
plating to a final concentration of 50 µM in 1% DMSO. Plates were fixed every 12 186 
hours from 0 to 72 hours post EdU addition with 4% formaldehyde for 30 min. EdU 187 
detection was performed following manufacturer’s indications and cells were stained 188 
with DAPI as previously described. Controls of GFP signal quenching and EdU positive 189 
spots detection in the absence of EdU in infected and uninfected cells were included in 190 
each experiment. 191 
 192 
In vivo activity against L. donovani 193 
Sodium stibogluconate sensitive (SSG) L. donovani (MHOM/ET/67/HU3) amastigotes 194 
were isolated from donor RAG1.B6 mouse. Freshly isolated parasites were re-195 
suspended in RPMI1649 media at a concentration of 1 × 10
8 
/ml.  196 
On day 0 female BALB/c mice (20 g; Charles River, Margate, UK) were infected 197 
intravenously by the lateral tail vein with 2 × 10
7 
amastigotes (0.2 ml inoculum) and 198 
randomly assorted into four groups of five members.  199 
Drug treatment started 7 days post infection and continued until day 11. Groups were 200 
treated with either (i)  vehicle only, orally, twice daily for 5 days, (ii) miltefosine 201 
(Paladin Inc., Canada), 12 mg/Kg, orally, once daily for 5 days, (iii) with AmBisome 202 
(Gilead, USA) at 1mg/Kg intravenously for 3 days (day 7, 9 and 11 post infection), and 203 
(iv) compound 1 at 50 mg/Kg, orally, twice for 5 days. 204 
At day 14 post infection, all animals were sacrificed and the parasite burden was 205 
determined microscopically on Giemsa stained liver smears after methanol fixation. The 206 
number of amastigotes per 500 cells was counted microscopically (X100, oil 207 
immersion) and the parasite load normalized to untreated controls. 208 
 209 
Pharmacokinetic studies 210 
Experimental compounds were administered to BALB/c female mice (25 g weight) by 211 
oral gavage at 50 mg/kg dose at a volume of 20 ml/kg. All mice were treated during the 212 
fed state. Drugs were administered as 10% 70:30 Tween80: EtOH/ddH2O suspensions 213 
and the blood sampling scheme was: 15, 30 and 45 minutes, 1, 1.5, 2, 3, 4, 8 and 24 214 
hours. At each time-point, 10 µL of blood were taken from the lateral tail vein from 215 
three animals. LC-MS was used for the establishment of compound concentration in 216 
blood with a sensitivity of LLQ = 1–5 ng/ml in 25 ml blood. The concentration of each 217 
drug was calculated in the peripheral total blood compartment. The non-compartmental 218 
data analysis was performed with WinNonlin 5.0 (Pharsight) and supplementary 219 
analysis was performed with GraphPad Prism (GraphPad Software). 220 
 221 
RESULTS 222 
Assay development 223 
In this intra-macrophage system the infection process was performed “in bulk” prior to 224 
the dispensation of the cell suspension in the assay plates, to eliminate any possible intra 225 
well variation and to increase the robustness of the assay.  226 
Copies of identical plates were prepared to allow fixing and staining at different time 227 
points and plotting of the growth curve. Cells were fixed with formaldehyde prior to 228 
DAPI staining. DAPI was used to detect the nucleus of THP-1 cells and GFP to detect 229 
intracellular amastigotes using the image analysis algorithm described in materials and 230 
methods. When performed for large scale screening of compounds, the assay had an 231 
average throughput of 40 plates/run (two runs/week-240,000 wells/week) and the 232 
average Z’ calculated at 96h using the AM/MAC output was 0.59 ± 0.12. 233 
 234 
Effect of horse serum on extracellular amastigotes 235 
The presence of extracellular parasites was determined by visual inspection of the plates 236 
at each time point. The assay media used reduced serum level, 2% serum instead of 237 
10% normally in the complete growth media for culture of THP-1 cells, to minimize the 238 
growth of extracellular parasites. Neither the presence of HS nor the reduced quantity of 239 
FBS significantly affected the THP-1 counts (Fig.1A). When cells were incubated with 240 
FBS, an increase in the extracellular parasites load could still be seen over the four days 241 
of incubation. In contrast, the few extracellular parasites present after seeding in the 242 
presence of HS-containing media, were killed within few hours of incubation. This 243 
difference could not be recorded when cells where stained with DAPI since extracellular 244 
parasites were removed with the washing steps required to remove the dye after 245 
staining. This was overcome by the use of Draq5, a nuclear dye that can be added with 246 
formaldehyde in a single step and does not need to be washed out. Figure 1B illustrates 247 
the difference in the content of extracellular parasites when infected THP-1 cells were 248 
incubated for four days in the presence of FBS or HS (Draq 5 staining).  249 
 250 
Effect of HS on L. donovani intracellular amastigotes 251 
The number of amastigotes per host cell (AM/MAC) at each time point (24h, 48h, 72h, 252 
96h) was plotted to determine the growth of the intracellular amastigotes, both in the 253 
presence of FBS and HS (Fig.1C). Differentiated THP-1 cells do not replicate, therefore 254 
the increase in the total number of amastigotes was not influenced by the increase of the 255 
number of host cells (24, 25). 256 
In the presence of FBS 2%, the number of AM/MAC increased on average from 1.5 to 257 
4.7 over 96h. When HS was used in the assay media at the same concentration, the 258 
AM/MAC increased from 1.6 to 3.6 over the 96 h of incubation, with a linear increment 259 
in the initial 72 hours post plating. When FBS was used, the presence of extracellular 260 
parasites and the potential of host cell reinfection prevented the replication rate to be 261 
accurately evaluated. At the same time, the use of HS ensured the elimination of any 262 
extracellular parasites after few hours of incubation, removing possible influence of re-263 
infection in the observed increase and allowed any observed growth to be attributed to 264 
intracellular replication. Figures 1D and 1E show infected THP-1 cells fixed and stained 265 
with DAPI 24h and 96h post plating. These experiments were carried out in the 266 
presence of 0.5% DMSO, that is the concentration found in each well when compounds 267 
are screened. This concentration did not significantly affect either the number of host 268 
cells or the replication of intracellular amastigotes when compared to a parallel 269 
experiment without DMSO (data not shown).  270 
It was also observed that the shape of the intracellular parasite was influenced by the 271 
serum used. In presence of FBS the intracellular amastigotes were elongated (having 272 
similarity with extracellular amastigotes) while they were more round and amastigote-273 
like when incubated in the presence of HS (Fig.1F), an observation previously made 274 
(26). 275 
 276 
Edu incorporation 277 
The optimal EdU concentration and exposure time were initially determined. THP-1 278 
cultures infected with L. donovani amastigotes were incubated with increasing amounts 279 
of EdU for different periods of time in a single experiment that was processed at once to 280 
detect the EdU incorporated into amastigotes’ DNA. Analysed images showed that 281 
amastigotes were able to significantly incorporate EdU with an increasing and sustained 282 
rate when exposed to 50 µM EdU for at least 12 hours (Fig. 2A); the incorporation rate 283 
achieved a plateau after 72 hours of exposition without parasite number reduction and 284 
thus without apparent toxic effects. Uninfected cultures and cultures with no exposure 285 
to EdU were included as technical detection controls.  286 
After the optimization of the experimental conditions, the incorporation of EdU over 287 
time by infected THP-1 cells maintained in HS-containing media was determined 288 
adding 50 µM of EdU 24 hours after plating and measuring EdU incorporation in 12-289 
hour lapses from 24 to 72 hours post plating. The number of amastigotes per 290 
macrophage was determined in both the GFP and in the EdU channel. Not all 291 
amastigotes incorporated EdU during the course of infection but the incorporation rate 292 
was consistent with the increase of intracellular parasite burden, reaching 40% parasites 293 
labelled as proliferating and demonstrating that the increase in the number of 294 
amastigotes per macrophage is to be attributed to replication (Fig. 2B). 295 
 296 
In vitro activity  297 
The activity of amphotericin B and miltefosine in FBS-containing media was in 298 
accordance with previously reported data (12), showing a pEC50 (pEC50= -Log (EC50)) 299 
equal to 7.17 and 6.56 respectively in the amastigotes/cell output. Both compounds 300 
maintained their activity when tested in the presence of HS (Fig.3). 301 
Compound 1 (Table 1) was assayed as part of the high throughput screening campaign 302 
against the kinetoplastids L. donovani, T. cruzi and T. brucei (16). This compound, 303 
when tested in the FBS containing media, exhibited a pEC50 of 7.8 in the intra-304 
macrophage assay as measured by the number of amastigotes/cell.  Measuring the 305 
percentage of infected macrophages, the compound showed no significant activity, with 306 
a maximum asymptote of 40%. When the compound was assayed in the presence of HS 307 
it was found to be inactive by both parameters (Fig.4). 308 
 309 
Pharmacokinetic studies 310 
Compound 1 was administered to the mice by oral gavage in a single dose for 5 days 311 
and no signs of pain, distress or local or systemic toxicity was observed. Values for 312 
AUC (Area Under the Curve) and plasma compound concentrations at peak and trough 313 
are given in Table 2. The values for AUC were high enough to ensure activity related to 314 
the calculated EC50 value. The exposure data were sufficiently favorable to warrant 315 
further in vivo testing. 316 
 317 
In vivo antileishmanial activity 318 
Amphotericin B (AmBisome), miltefosine and compound 1 were tested on L. donovani 319 
infected BALB/c mice. AmBisome and miltefosine were active in vitro both in the 320 
presence of FBS or HS. In vivo they decreased the parasite burden of the 99.52% and 321 
77.23% at 1 mg/kg i.v. and 12 mg/kg p.o. respectively, in accordance with previously 322 
reported data (27). In contrast, compound 1 at two daily doses of 50mg/kg only reduced 323 
the parasite burden of the 20% after 5 days of treatment (Table 3).  324 
 325 
DISCUSSION  326 
Drug discovery for antileishmanial compounds has recently been focused on phenotypic 327 
rather than target based screens, due to the limited number of fully validated targets and 328 
issues of confirming on-target effects of active compounds (28, 29). However, the in 329 
vitro activity of test compounds frequently does not translate to in vivo activity, 330 
underlining the need for the development of new and more predictive in vitro assays 331 
adaptable to a high throughput screening.   332 
It has been demonstrated that the activity of antileishmanial drugs is host cell dependent 333 
(30). Primary host cells mimic the biological situation more accurately but are not 334 
compatible with the needs of a high throughput screen. Instead, immortalized human 335 
monocytic THP-1 cells, that can be differentiated into macrophage-like cells, are able to 336 
develop and sustain L. donovani infections (24, 31). Different high content screening 337 
assays using PMA-differentiated THP-1 cells infected with either promastigotes or 338 
amastigotes have been developed, confirming their suitability as L. donovani hosts (12-339 
14, 16). 340 
 341 
In comparison to traditional assays that provide information mainly on parasite 342 
viability, the use of HCS technologies permits the assessment of potential toxicity 343 
against the host cells and to observe morphological changes that can provide useful 344 
information to understand the mode of action of the compounds of interest (10). In our 345 
assay THP-1 cells were differentiated and infected “in bulk” and dispensed into assay 346 
plates containing the compounds to be tested as previously described (16). The use of 347 
cells that have been differentiated and infected “in bulk” assured a homogenous 348 
distribution of the infection throughout the plates, strongly reducing inter well 349 
variability, and eliminated the need of using intermediate plates loaded with test 350 
compounds.  351 
One limitation of this protocol is that it does not allow any wash steps after the 352 
dispensation of cells in the plate and that would remove extracellular parasites derived 353 
from the infection process or from the rupture of host cells during trypsinization or 354 
dispensing. This can be problematic as axenic amastigotes are adapted to grow in 355 
culture with an average doubling time of 6 hours and thus, after infection, any parasite 356 
that is not phagocytized by a host cell can grow over the incubation period and re-infect 357 
neighboring hosts. In addition, the pH of the assay media is higher than the pH of the 358 
culturing media and could contribute to the differentiation of the amastigotes to an 359 
intermediate form of the parasite similar to promastigotes. The primary objective in 360 
antileishmanial drug discovery is to identify compounds able to interfere with the 361 
growth and survival of the intracellular parasites rather than acting on the extracellular 362 
parasites. As the presence of HS in the media was found to kill extracellular parasites 363 
within a few hours of incubation, HS was included in the assay media in order to 364 
prevent the growth and establishment of an extracellular culture, without affecting the 365 
viability of the hosts or of the intracellular amastigotes. The use of HS-containing media 366 
allowed to reduce thenumber of washing steps following infection and ensured the 367 
elimination of any extracellular parasites deriving from a mechanical rupture of the host 368 
cell within a few hours following initial infection. We have also observed that, in the 369 
presence of HS, the intracellular parasites assumed a round shape, characteristic of the 370 
amastigote stage, whereas they were more elongated when incubated with FBS. The 371 
ability of HS to kill extracellular parasites and to push the differentiation of intracellular 372 
amastigotes towards a more amastigote-like form are in accordance with what 373 
previously reported by Frothingham and Lehtimaki (26). 374 
The antiparasitic effect of serum components has already been described. The 375 
trypanolytic factor present in human serum is responsible for the inability of 376 
Trypanosoma brucei brucei to infect humans (32). In the case of Leishmania and horse 377 
serum there is no evidence of a similar mechanism. However, it is known that horse 378 
serum is less rich in nutrients and growth factors compared to foetal bovine serum and 379 
this could contribute to the observed effect. 380 
When FBS-containing media was used in this assay, the presence of extracellular 381 
parasites, and hence the simultaneous contribution of replication and re-infection to the 382 
observed increase of the number of amastigotes/macrophages over time, did not permit 383 
us to conclusively establish the replication rate. A previous report on the doubling time 384 
of intracellular amastigotes in the presence of FBS and in absence of extracellular 385 
parasites, extrapolated a replication rate of approximately 12 days from the 7 days 386 
growth curve (14). In the assay developed in this work, when HS was included in the 387 
media, the number of amastigotes/macrophages doubled from 24h to 72h and, since no 388 
extracellular parasites were visible, it was possible to attribute this proliferation solely 389 
to the replication of the intracellular parasite, as demonstrated with the EdU 390 
incorporation assay. The replication observed in this horse serum intra-macrophage 391 
assay was lower than the one observed in the in vivo mouse model (18) or hamster 392 
model (19), but was similar to that observed in the ex vivo splenic explant culture from 393 
hamster infected with L. donovani described by Osorio et al. (20), where the number of 394 
amastigotes/macrophage doubled in the first 48 hours post plating. The two-day 395 
doubling time we observed in the in vitro system described in the present work, is also 396 
in accordance with the doubling time observed by other groups when THP-1 cells were 397 
infected with L. donovani promastigotes (12, 31). Even if results obtained in different 398 
assays using different strains are difficult to compare, the fact that we observed and 399 
were able to quantify the replication of intracellular parasites in the horse serum in vitro 400 
system, is of importance for the development of more predictive in vitro assays (7)..  401 
De Muylder et al. described the use of a media containing 5% HS and 5% FBS to wash 402 
differentiated THP-1 cells after infection with L. donovani promastigotes (12). The 403 
choice of use of HS in the washing media was not discussed in this report, but, 404 
considering that differentiation and infection were performed in wells, it appears that 405 
HS was chosen to assist in the elimination of the extracellular parasites after infection, 406 
prior to compounds’ addition. In the same report, it appears that HS was not included in 407 
the assay media and the effects of horse serum on the replication and appearance of 408 
intracellular amastigotes were not characterised. 409 
DNA synthesis rate is highly up-regulated during the replication process representing a 410 
good biomarker for proliferation. The incorporation of thymidine analogues during the 411 
active S-phase in dividing cells has been widely used as a molecular biomarker for 412 
proliferation (21). BrdU has been previously used to qualitatively identify the 413 
intracellular amastigotes as a replicating population, following THP-1 infection with L. 414 
donovani promastigotes (13). In the present work, to confirm that the increase in the 415 
number of amastigotes/macrophages observed when HS was included in the assay 416 
media was attributable to replication, the EdU pycolil-azide combined methodology was 417 
used, allowing the identification of those amastigotes that have entered into S-phase 418 
while infecting macrophages, without compromising GFP fluorescence and amastigote 419 
identification. The increase of EdU incorporation over time specifically identifies 420 
proliferation events that take place within the macrophages, since the addition of EdU 421 
after 24 hours of incubation with horse serum ensured that only intracellular parasites 422 
would have been exposed to the thymidine analogue.  The EdU incorporation rate was 423 
similar to the estimated replication rate based on direct counting. The detection of non-424 
labelled parasites after long incubation periods suggests there might be a non-dividing 425 
subpopulation of amastigotes, in accordance with observations by Kloehn et al. in 426 
murine L. mexicana lesions (33). 427 
To validate this in vitro assay, two reference drugs, amphotericin B and miltefosine and 428 
the GSK compound 1 were tested in the intra-macrophage assay in the presence of FBS 429 
or HS and using an in vivo animal model, allowing for a comparison of the in vitro and 430 
in vivo activities. The in vitro activities of amphotericin B and miltefosine were in 431 
accordance with previous reports and no significant difference between their activity in 432 
the presence of FBS or HS was observed. Compound 1 was selected as a proof of 433 
concept study, as it showed a pEC50 value higher than amphotericin B in the presence of 434 
FBS (pEC50=7.8) but was inactive when tested in the presence of HS (pEC50<4.3). 435 
When tested in vivo, amphotericin B and miltefosine confirmed their activity, reducing 436 
the parasite burden by 99.52% and 77.23% respectively. In contrast, compound 1 was 437 
inactive when administered orally, reducing the parasite burden by 20.93% only. Since 438 
compound 1 possesses lead-like physicochemical properties (34) (Table 1) and 439 
reasonable bioavailability in mice in terms of Cmax and AUC (Table 2), we propose 440 
that factors other than pharmacokinetics might contribute to the lack of efficacy in the 441 
infection model, such as poor pharmacodynamics at the site of action. In particular, we 442 
suggest it could be linked to its lack of activity in the in vitro horse serum intra-443 
macrophage assay, in contrast with the high pEC50 value obtained when a media 444 
containing FBS was used (AM/MAC output). Several reasons could explain the lack of 445 
activity of compound 1 in HS: compound structure related properties, the lack of 446 
activity against intracellular replicating amastigotes in horse serum, or the compound 447 
could be active only against the extracellular amastigotes forms found in presence of 448 
FBS. Even though the exact mode of action of compound 1 has not been clarified, the 449 
correlation between the results obtained  in the in vitro horse serum intra-macrophage 450 
assay and the in vivo mouse model seem to suggest that the in vitro results obtained 451 
with horse serum translate to the in vivo animal model and that this assay mimics an in 452 
vivo L. donovani infection more accurately than the same assay with FBS. In fact, the 453 
standard drugs miltefosine and amphotericin B were active in in vitro and in vivo assays 454 
and compound 1 was inactive both in vitro when horse serum was used, irrespectively 455 
of the output used for the determination of its pEC50, and in vivo.  456 
This is, to our knowledge, the first report on the inclusion of horse serum in the assay 457 
media for the whole assay, not only to completely remove the extracellular parasites and 458 
impede their growth over the incubation period, but also to increase the replication rate 459 
of the intracellular amastigotes from the 12 days observed with FBS (14)  to 2 days. 460 
The activity of the test compounds in vivo correlated with what observed in vitro in the 461 
intra-macrophage horse serum assay. Although the causes of the different in vitro 462 
activities of compound 1 in FBS and HS are still not clear, these results suggest that the 463 
assay here described is a right step towards the development of a translational in vitro 464 
assay and represents an incentive for the deeper investigation of its application in 465 
antileishmanials drug discovery. 466 
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Table 1 Physicochemical properties of compound 1. MW: Molecular weight, MF: 589 
Molecular formula, aring: number of aromatic rings, clogp: calculated partition-590 
coefficient between n-octanol and water, hba: hydrogen-bond acceptor, hbd: hydrogen-591 
bond donor, heavy: number of heavy atoms (no hydrogen atoms), tpsa: total polar 592 















#1 50 227.0 4.5 401.0 438.1 8.8 
#2 50 154.0 3.1 339.7 358.4 7.2 
#3 50 95.9 1.9 227.6 238.8 4.8 
Average 159.0 3.2 322.8 345.1 6.9 
SD 65.7 1.3 87.9 100.3 2.0 
 595 
Table 2 Blood pharmacokinetic parameters in Balb/c mice after single oral gavage 596 
administration of compound 1 (actual dose= 50 mg/kg). DNAUC and Cmax/D, dose 597 
normalized value of AUC and Cmax (AUC or Cmax/Experimental dose). 598 
 599 
Tested compound Administration % inhibition 95% C.I. 
AmBisome  1 mg/kg i.v. (D7, D9 and D11) 99.52 0.28 
Miltefosine 12 mg/kg p.o. x 5 days 77.23 12.41 
Compound 1 50 mg/kg BID x 5 days 20.93 8.34 
 600 
Table 3 Activity of amphotericin B, miltefosine and compound 1 against Balb/c mice 601 
infected with L. donovani HU3 (N=5). i.v.= intravenous, p.o.=oral, BID (“bis in die”)= 602 
twice a day, C.I.=confidence interval. 603 
 604 
FIGURES LEGENDS 605 
Fig.1  A) Average number of THP-1 cells (6 fields) in assay media containing 2% FBS, 606 
10% FBS, 2% HS, 10% FBS. B) THP-1 cells (DRAQ5, red) infected with L. donovani 607 
(green) in the presence of FBS 2% or HS 2% at 96h (20x, air objective. C) Evolution of 608 
the number of amastigotes per macrophages (AM/MAC) in the presence of HS 2% 609 
(blue) or FBS 2% (red) and 0.5% DMSO. Number of amastigotes per total macrophages 610 
are represented, final percentage of infection 86% in FBS and 78% in presence of HS. 611 
D) THP-1 cells (DAPI, red) infected with L. donovani (green) in the presence of FBS 612 
2% at 24 and 96h (20x, air objective). E) THP-1 cells (DAPI, red) infected with L. 613 
donovani (green) in the presence of HS 2% at 24 and 96h (20x, air objective). F) THP-1 614 
cells (DAPI, red) infected with L. donovani (green) in the presence of FBS 2% or HS 615 
2% at 96h (40x, water objective). 616 
 617 
Fig. 2 A) Percentage of intracellular L.donovani amastigotes incorporating EdU (100, 618 
50, 10, 5, 1, 0µM). B) Number of amastigotes per macrophage in infected THP-1 cells 619 
processed for EdU detection. Amastigotes were detected as GFP positive spots (white 620 
squares) or EdU (50 µM) positive spots (black circles). 621 
 622 
Fig. 3 Dose response curves of amphotericinB-FBS (A), miltefosine-FBS (B), 623 
amphotericinB-HS (C) and miltefosine-HS (D). Curves were generated from 11 points, 624 
1/3 dilutions at a maximum concentration of 50µM, Data are presented as mean and SD, 625 
4 replicates. 626 
 627 
Fig. 4 Dose response curves of compound 1 tested in the presence of FBS (squares) or HS 628 
(circles). Curves were generated from 11 points, 1/3 dilutions at a maximum concentration of 629 
50µM. Data are presented as mean and SD, 4 replicates.  630 
 631 
Fig. 5. Whole blood levels in BALB/c mice after single oral gavage administration of 632 
compound 1 (actual dose= 50 mg/kg) The dotted line represents the EC50 value for 633 
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Molecular formula, aring: number of aromatic rings, clogp: calculated partition-
coefficient between n-octanol and water, hba: hydrogen-bond acceptor, hbd: hydrogen-
bond donor, heavy: number of heavy atoms (no hydrogen atoms), tpsa: total polar 
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